SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-058660
Filing Date
2021-11-12
Accepted
2021-11-12 16:04:05
Documents
80
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0921_jaspertherap.htm   iXBRL 10-Q 2311981
2 CERTIFICATION f10q0921ex31-1_jasper.htm EX-31.1 11451
3 CERTIFICATION f10q0921ex31-2_jasper.htm EX-31.2 11221
4 CERTIFICATION f10q0921ex32-1_jasper.htm EX-32.1 6116
10 GRAPHIC image_001.jpg GRAPHIC 116694
  Complete submission text file 0001213900-21-058660.txt   8073429

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE jspr-20210930.xsd EX-101.SCH 78114
6 XBRL CALCULATION FILE jspr-20210930_cal.xml EX-101.CAL 27170
7 XBRL DEFINITION FILE jspr-20210930_def.xml EX-101.DEF 283815
8 XBRL LABEL FILE jspr-20210930_lab.xml EX-101.LAB 581034
9 XBRL PRESENTATION FILE jspr-20210930_pre.xml EX-101.PRE 298540
11 EXTRACTED XBRL INSTANCE DOCUMENT f10q0921_jaspertherap_htm.xml XML 1048022
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39138 | Film No.: 211403321
SIC: 2836 Biological Products, (No Diagnostic Substances)